Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms

NEWARK, N.J., July 13 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology-based Life Science company announced today that at ATS Labs using the EPA required AOAC Sporicidal Test, the Hospital Grade of its Ygiene(TM) formula produced a 100% Total Kill of live spores in seven (7) minutes. This EPA required AOAC Sporicidal Test utilizing spore impregnated then knotted suture loops and porous cylinders is an extremely difficult test to pass, especially when starting with over one million Clostridium Sporogenes spores. The rapid elimination of these health threatening microorganisms, in the spore form, at health care facilities will reduce the incidents of Hospital Acquired Infections (HAI) and the associated loss of lives. From one million spores to zero in 7 minutes is up to 50 times faster than the competition. This means money and lives saved at every health care facility around the world.

Examples of commonly used antimicrobials in health care facilities including hospitals which cannot claim passing this EPA sporicide/sterilant test include CaviCide(R), Medica DC 10(TM), Wavicide 06 Plus(TM) and Myacide(R) GA 25. While these antimicrobials may eliminate easily eradicated bacteria and some viruses, they have no effect on spores and therefore cannot provide truly disinfected and sterile environments in the health care arena. Examples of antimicrobials which have passed the EPA required test include Steris(R) Hydrogen Peroxide Sterilant. However, special protective equipment and highly trained professionals are required to correctly apply this antimicrobial. In addition this product takes a full 90 minutes of direct contact to eliminate spores. In comparison while Steris(R) Spor-Klenz RTU may be easier to apply, it can take up to 5.5 hours to eliminate spores. These currently used commercial products have significant shortcomings by being ineffective, cumbersome to use or require very lengthy periods of time to be effective at all in eliminating health threatening spores.

A room temperature, cold, sporicide/sterilant with the rapid kill demonstrated by Ygiene(TM) Hospital Grade will provide a huge economic advantage for future users. By delivering a safe easy to use and a much quicker turn around time for total sterilization of equipment and facilities, BioNeutrals Ygiene(TM) will greatly reduce the waste of human resources and capital currently experienced in health care facilities and will maximize value to the user & increased safety for the patients.

Dr. Andy Kielbania PhD, Chief Scientist at BioNeutral Group stated: "These independent lab validation results from ATS show that we have developed what we believe is the best, and I emphasize the best, antimicrobial coming to the market. By using the strategy of raising the bar for antimicrobial performance, we believe our superior Ygiene(TM) Hospital Grade antimicrobial will provide much cleaner, safer and healthier environments in health care facilities globally. Reducing the loss of lives and wasteful expenditures of human resources and money by diminishing Hospital Acquired Infections (ACI) is our goal. These independent test results stand by themselves and are consistent with our achieving our goals and objectives. These results are incredible and validate all of our efforts."

Dr. Philip M. Tierno Jr. MS, PhD Chairman of BioNeutral Group Scientific Advisory Board stated: "The sporocidal data on Ygiene(TM)'s performance that I reviewed is quite impressive. Two immediate and important applications of Ygiene(TM) come to mind:

1- Perhaps the biggest challenge facing hospitals worldwide is eradication of Clostridium difficile spores in the environment in a timely fashion thereby reducing or eliminating possible nosocomial spread. Ygiene(TM) safely and efficiently solves that problem.

2- The safe, rapid and effective killing of all multi-antibiotic drug resistant pathogenic bacteria like MRSA, VRE, ESBL, AmpC, KPC, etc in the hospital environment is again easily accomplished by Hospital Grade Ygiene(TM). In short, having met the EPA's AOAC Sporocidal Test standard in such a timely fashion is an impressive and significant accomplishment."

"Killing these extremely dangerous microorganisms on a flat non-porous surface is one thing. Having now proven that our Hospital Grade Ygiene(TM) can hunt them down and kill them where ever they may hide is something else entirely" said Stephen J. Browand CEO BioNeutral Group Inc. "These test results along with a number of others soon to be announced will bring our various formulations to the forefront of scientific breakthroughs discovered in this millennium. All of our technology was developed under the mantra of creating science to not only save lives but also protect the environment; this formula falls well within those guidelines."

About ATS Labs:

ATS Labs, is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
2. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
3. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
4. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
5. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
6. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
7. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
8. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
9. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
10. New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More
11. TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):